PD- 1, whose full name is programmed death 1 and English name is Programmed Death 1, is an important immunosuppressive molecule and a member of CD28 superfamily. Immunoregulation of PD- 1 is of great significance in anti-tumor, anti-infection, anti-autoimmune diseases and organ transplantation survival. Its ligand PD-L 1 can also be used as a target, and the corresponding antibody can also play the same role.
Working principle of PD-L 1 corrosion inhibitor
PD-L 1, whose full name is programmed death receptor-ligand 1 and English name is programmed cell death-ligand1,is the first kind of transmembrane protein with a size of 40kDa. Under normal circumstances, the immune system will react to foreign antigens gathered in lymph nodes or spleen, and promote the proliferation of T cells with antigen specificity. The combination of programmed cell death receptor-1(PD- 1) and programmed cell death ligand-1(PD-L 1) can transmit inhibitory signals and reduce the proliferation of T cells.
Working principle of PD-L 1/PD- 1 corrosion inhibitor
The representative drugs of PD- 1 are:
Keytruda (trade name: Pembrolizumab) of Merck is the first PD- 1 inhibitor listed in the United States, which is used for the second-line treatment of advanced melanoma. At present, tumor immunotherapy is being studied in the fields of breast cancer, lymphoma, lung cancer, sarcoma, renal cell cancer, melanoma, colorectal cancer, bladder cancer, hematological cancer, prostate cancer and bone marrow cancer.
PD-L 1/PD- 1 drug Keytruda
Bristol-Myers Squibb's PD- 1 inhibitor Opdivo (drug name: Nibozumab) was first approved by FDA in 20 14 for the treatment of melanoma patients.
PD-L 1/PD- 1
The representative drugs of PD-L 1 are:
Tecentriq (drug name: Atezolizumab) is the first PD-L 1 inhibitor and the first immunotherapy drug approved for the treatment of this tumor, which was developed by Roche.
PD-L 1/PD- 1 drug Tecentriq
Imfinzi is a PD-L 1 inhibitor developed by AstraZeneca. FDA first approved it for locally advanced or metastatic bladder cancer on 20 17.
PD-L 1/PD- 1
Recently, PD- 1 inhibitors (Opdivo and Keytruda) have been listed in the mainland, which is undoubtedly the biggest good news for many patients. But then, in the face of the huge cancer population base, can mainland hospitals (or pharmacies) supply it in time? This is an urgent problem to be solved. When immunotherapy drugs are included in medical insurance is also a concern of cancer patients, and it is not waiting for people.
Hong Kong, a world-class seaport city, has a unique geographical location, an environment under the capitalist system and a medical standard that is in line with international standards. Relying on this advantage, Hong Kong Comprehensive Cancer Center provides more patients in need with the latest treatment schemes and drugs that meet international standards, and has mature clinical strength in the treatment of major diseases such as lung cancer, colorectal cancer and breast cancer. 20 15 hong kong comprehensive cancer center and Victoria harbour health reached a strategic cooperative relationship. Through the Victoria Harbour Health Center, you can make an appointment with an oncologist directly. Under the doctor's diagnosis, you can directly know whether the patient is suitable for PD- 1/PD-L 1 immunotherapy, or you can directly take drugs.
As the first comprehensive day cancer clinic in Asia and the only comprehensive day cancer clinic in Hong Kong, Hong Kong Comprehensive Cancer Center provides high-quality and comprehensive one-stop and interdisciplinary cancer diagnosis and treatment services to ensure that every patient can get comprehensive professional advice and the most suitable treatment plan. Tecentreq is the latest PD-L 1 inhibitor, which has been approved for urothelial cancer. According to the latest clinical research, positive progress has been made by adding Tecentreq to the second-line combined therapy of liver cancer.
For most advanced solid tumors, extending the survival time beyond 2.5 ~ 6 months can be considered as clinically significant. PD- 1 antibody and PD-L 1 antibody can easily meet the above requirements in sensitive population. Exploring the markers to predict the curative effect and designing reasonable combined immunotherapy will be the research focus of tumor immunotherapy in the near future. Because of the slight difference between PD- 1 antibody and PD-L 1 antibody, the combination therapy based on PD-L 1 antibody may have greater market potential.